RTI Biologics Beats on Both Top and Bottom Lines

Share this story with your network

By Seth Jayson

updated 8/2/2012 5:55:22 AM ET

RTI Biologics reported earnings on July 31. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q2), RTI Biologics beat expectations on revenues and beat expectations onearnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share dropped.

Gross margins improved, operating margins increased, net margins contracted.

Revenue details
RTI Biologics reported revenue of $45.2 million. The seven analysts polled by S&P Capital IQ anticipated a top line of $44.2 million on the same basis. GAAP reported sales were 3.9% higher than the prior-year quarter’s $43.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.05. The seven earnings estimates compiled by S&P Capital IQ predicted $0.04 per share. GAAP EPS of $0.02 for Q2 were 50% lower than the prior-year quarter’s $0.04 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross marginwas 47.9%, 260 basis points better than the prior-year quarter. Operating margin was 8.9%, 190 basis points better than the prior-year quarter. Net margin was 2.9%, 170 basis points worse than the prior-year quarter.

Looking ahead
Next quarter’s average estimate for revenue is $43.8 million. On the bottom line, the average EPS estimate is $0.04.

Next year’s average estimate for revenue is $177.9 million. The average EPS estimate is $0.16.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 211 members out of 221 rating the stock outperform, and 10 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 46 give RTI Biologics a green thumbs-up, and one gives it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on RTI Biologics is outperform, with an average price target of $4.78.

Over the decades, small-cap stocks, like RTI Biologics have provided market-beating returns, provided they’re value priced and have solid businesses. Read about a pair of companies with a lock on their markets in “Too Small to Fail: Two Small Caps the Government Won’t Let Go Broke.” Click here for instant access to this free report.

  • Add RTI Biologics to My Watchlist.

 

Source: http://www.msnbc.msn.com/id/48470555/ns/business-motley_fool/#.UB_0k8ie4b8

Leave a Comment

Your email address will not be published. Required fields are marked *

*